MiR-34a-FOXP1 Loop in Ovarian Cancer

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2023 Aug 7

PMID 37546627

Authors

Esra Dirimtekin

Maria Mortoglou

Ceren Alavanda

Asmaa Benomar Yemlahi

Esra Arslan Ates

Ilter Guney

Pinar Uysal-Onganer

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is the main cause of gynecological cancer mortality in most developed countries. microRNA (miR) expression dysregulation has been highlighted in human cancers, and miR-34a is found to be downregulated and associated with inhibition of tumor growth and invasion in several malignancies, including OC. The winged helix transcription factor forkhead box P1 (FOXP1) is reported as either an oncogene or tumor suppressor in various cancers. This study aimed to elucidate potential clinical and biological associations of miR-34a and transcription factor FOXP1 in OC. We investigated nine OC patients' blood samples and two OC cell lines (SKOV-3 and OVCAR-3) using quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR) to determine both miR-34a and FOXP1 expressions. We have found that miR-34a and FOXP1 are reversely correlated in both in vitro and in vivo. Inhibition of miR-34a transiently led to upregulation of FOXP1 mRNA expression and increased cellular invasion in vitro. Our data indicate that miR-34a could be a potential biomarker for improving the diagnostic efficiency of OC, and miR-34a overexpression may reduce OC pathogenesis by targeting FOXP1.

Citing Articles

Low Magnetic Field Exposure Alters Prostate Cancer Cell Properties.

Lange S, Inal J, Kraev I, Dart D, Uysal-Onganer P Biology (Basel). 2024; 13(9).

PMID: 39336161 PMC: 11428832. DOI: 10.3390/biology13090734.

References

He M, Gao L, Zhang S, Tao L, Wang J, Yang J . Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric Cancer. 2013; 17(3):431-41. DOI: 10.1007/s10120-013-0313-3. View

Resnick K, Alder H, Hagan J, Richardson D, Croce C, Cohn D . The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2008; 112(1):55-9. DOI: 10.1016/j.ygyno.2008.08.036. View

Naghizadeh S, Mohammadi A, Duijf P, Baradaran B, Safarzadeh E, Cho W . The role of miR-34 in cancer drug resistance. J Cell Physiol. 2020; 235(10):6424-6440. DOI: 10.1002/jcp.29640. View

Wang Y, Li N, Ren Y, Zhao J . Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis. J Obstet Gynaecol Res. 2022; 48(9):2270-2284. DOI: 10.1111/jog.15326. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Xiao J, He B, Zou Y, Chen X, Lu X, Xie M . Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis. Sci Rep. 2016; 6:30437. PMC: 4960649. DOI: 10.1038/srep30437. View

Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J . Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer. 2016; 16:102. PMC: 4754861. DOI: 10.1186/s12885-016-2135-2. View

Misso G, Di Martino M, De Rosa G, Farooqi A, Lombardi A, Campani V . Mir-34: a new weapon against cancer?. Mol Ther Nucleic Acids. 2014; 3:e194. PMC: 4222652. DOI: 10.1038/mtna.2014.47. View

Luo Y, Liu F, Ma J, Fu Y, Gui R . A novel epigenetic regulation of circFoxp1 on Foxp1 in colon cancer cells. Cell Death Dis. 2020; 11(9):782. PMC: 7502072. DOI: 10.1038/s41419-020-03007-6. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Charkhchi P, Cybulski C, Gronwald J, Wong F, Narod S, Akbari M . CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020; 12(12). PMC: 7763876. DOI: 10.3390/cancers12123730. View

12.

Gupta K, Gupta V, Naumann R . Ovarian cancer: screening and future directions. Int J Gynecol Cancer. 2019; 29(1):195-200. DOI: 10.1136/ijgc-2018-000016. View

13.

Alshamrani A . Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?. Front Oncol. 2020; 10:1084. PMC: 7396563. DOI: 10.3389/fonc.2020.01084. View

14.

Liu A, Qu H, Yu C, Sun P . Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by up-regulating miR-217 and down-regulating FOXP1. J Cell Mol Med. 2018; 22(9):4034-4044. PMC: 6111824. DOI: 10.1111/jcmm.13483. View

15.

Koon H, Ippolito G, Banham A, Tucker P . FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2007; 11(7):955-65. PMC: 4282158. DOI: 10.1517/14728222.11.7.955. View

16.

Li Y, Zeng C, Hu J, Pan Y, Shan Y, Liu B . Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression. J Hematol Oncol. 2018; 11(1):89. PMC: 6029165. DOI: 10.1186/s13045-018-0632-2. View

17.

Mortoglou M, Miralles F, Arisan E, Dart A, Jurcevic S, Lange S . microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci. 2022; 23(3). PMC: 8835847. DOI: 10.3390/ijms23031275. View

18.

Slabakova E, Culig Z, Remsik J, Soucek K . Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 2017; 8(10):e3100. PMC: 5682661. DOI: 10.1038/cddis.2017.495. View

19.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

20.

Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R . Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008; 582(10):1564-8. DOI: 10.1016/j.febslet.2008.03.057. View